Guidance on OBMEA for rare diseases
Guideline
Guidance on use and implementation of outcome-based managed entry agreements for rare disease treatments including considerations for successful implementation.
- Project
- IMPACT HTA
- Funding
- Horizon 2020
- Project status
- Completed 2021
- HTA domains
- Aspects Beyond HTA
- Categories
- Pricing/Payer
- Technology
- Medicines
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.